<DOC>
	<DOCNO>NCT01724931</DOCNO>
	<brief_summary>The purpose study determine whether aminopterin effective treatment rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>Aminopterin Dose Finding Treatment Methotrexate-Naïve Rheumatoid Arthritis</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled , dose range study evaluate safety , efficacy , pharmacokinetic property ( absorption , distribution excretion ) aminopterin follow oral administration subject active rheumatoid arthritis ( ≥ 6 tender ≥ 6 swollen joint ) treat methotrexate ( MTX ) . Subjects randomized one three treatment : placebo , 1 mg LD-aminopterin , 3 mg LD-aminopterin 1:1:1 ratio . The study hypothesis 3 mg LD-aminopterin per week effective treating rheumatoid arthritis compare placebo .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<criteria>1 . &gt; 18 year age . 2 . A diagnosis RA establish ACR/EULAR 2010 criterion apply patient : 1 ) &gt; 1 joint definite clinical synovitis ( swell ) ; 2 ) synovitis well explain another disease . Add score category AD ; score &gt; 6/10 require study entry . A . Joint involvement : 1 large joint=0 ; 210 large joints=1 ; 13 small joint ( without involvement large joints=2 ; 410 small joint ( without involvement large joint ) =3 ; &gt; 10 joint ( least 1 small joint ) =5 . B. Serology ( least 1 test result need classification ) : Negative RF negative ACPA=0 ; Lowpositive RF lowpositive ACPA=2 ; Highpositive RF highpositive ACPA=3 . C. Acutephase reactant ( least 1 test result need classification ) : Normal CRP normal ESR=0 ; Abnormal CRP abnormal ESR=1 . D. Duration symptom : le 6 weeks=0 ; 6 week greater=1 . 3 . Class I , II III functional accord ACR 1992 revise criterion classification global functional status RA . 4 . RA active , define ≥ 6 swollen joint ≥ 6 tender joint . 5 . Ability understand sign write informed consent . 6 . For sexually active men woman childbearing potential , adequate form contraception . 7 . For premenopausal woman , negative pregnancy test , obtain within 1 week prior first study drug dose . 8 . Negative serology hepatitis B hepatitis C. 9 . The follow screening laboratory blood test must follow value , clinically significant determine PI Medical Monitor : WBC WNL ; absolute neutrophil count &gt; low limit normal ; platelet count WNL ; hemoglobin &gt; 10.0 g/dL ; AST WNL . 10 . Adequate renal function : GFR estimate CockcroftGault formula &gt; 60 ml/min 1 . Known history hepatitis , HIV infection , interstitial lung disease . 2 . Alcohol consumption regular basis unwilling , unable , discontinue consumption study period . 3 . Prior methotrexate aminopterin therapy . 4 . Prior biologic drug therapy ( e.g. , etanercept , adalimumab , infliximab ) . 5 . Within 2 week prior Study Day 0 , Study Day 0 , time study , use follow medication may result drug/drug interaction AMT : trimethoprim without sulfamethoxazole ; sulfonamide ; sulfonylurea ; pyrimethamine ; triamethamine ; dipyridamole ; colchicine ; probenecid ; aminoglycosides ; theophylline ; phenytoin ; folinic acid ( i.e. , leucovorin ) . 6 . At Study Day 0 use DMARDs biologics ( except antimalarial ) include oral injectable gold , azathioprine , penicillamine , sulfasalazine cyclosporine . Subjects previously treat medication eligible provide 28 day washout complete prior Study Day 0 . Antimalarial continue dose administer dose 8 week Study Day 0 , administer dose throughout study . NSAIDs corticosteroid ( ≤ 10 mg prednisone equivalent/day ) may continue dose use stable dose two week prior Study Day 0 , continue dos throughout study . 7 . Use corticosteroid excess 10 mg prednisone equivalent/day . 8 . Known concurrent malignancy except basal squamous cell skin carcinoma , cervical carcinoma situ . 9 . Concurrent participation another clinical trial involve experimental treatment within 30 day Study Day 0 . 10 . Current uncontrolled infection , cardiovascular , renal , pulmonary , hepatic GI condition interfere conduct trial pose morbid risk . 11 . Investigator 's opinion concurrent disease condition impair subject 's ability complete trial : include psychological , familial , sociological , geographical medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>antifolate</keyword>
	<keyword>antiinflammatory</keyword>
	<keyword>autoimmune disease</keyword>
	<keyword>hematological treatment</keyword>
	<keyword>rheumatic disease</keyword>
	<keyword>folic acid antagonist</keyword>
	<keyword>enzyme inhibitor</keyword>
</DOC>